| INOVIO PHARMACEUTICAL INC |
| USA |
| Gesundheit |
| US45773H4092 / A400EJ |
| GBM (Frankfurt) / INO (NASDAQ) |
| FRA:GBM, ETR:GBM, GBM:GR, NASDAQ:INO |
| - |
| https://inovio.com/ |
|
Inovio Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines for HPV-related diseases, cancer, and infectious diseases. The company’s work centers on DNA-based immunotherapies and vac..
>Volltext.. |
| 106.5 Mio. EUR |
| 81.43 Mio. EUR |
| - |
| -67.99 Mio. EUR |
| -60.13 Mio. EUR |
| -1.05 EUR |
| 7.14 Mio. EUR |
| 28.11 Mio. EUR |
| -71.86 Mio. EUR |
| 0.92 |
| -100% |
| 20.75% |
| - |
| - |
| - |
| - |
| INOVIO |
| 09.10.26 |
|